Datapoint: Sanofi Inks Deal for Provention Bio

French drugmaker Sanofi on March 13 revealed it has entered a $2.9 billion deal to acquire Provention Bio. The transaction nets Sanofi Tzield, Provention’s immunotherapy that stalls the progression of type 1 diabetes in adult and some pediatric patients. “The acquisition is a strategic fit for Sanofi at the intersection of the company’s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes,” the company said in a press release. Tzield was first approved by the FDA in November 2021, and Evaluate Pharma projects the drug will see $149 million in global sales by the end of 2024, growing to $1 billion in 2028.

From Evaluate Pharma

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today